A Study of Stereotactic Radiosurgery (SRS) for People With Lung Cancer That Has Spread to the Brain

The film gives the main points. The full list below is copied from the registry; the study team makes the final decision.

• Age18 Years to no maximum
• SexAll
• Healthy volunteersNo

You may be able to join if

• Histologic diagnosis of small cell lung cancer
• Radiographic diagnosis of up to 20 brain metastases on contrast-enhanced MRI
• Age 18 and above
• Performance status KPS 60-100/ECOG 0-2
• Female patients must be of non-reproductive potential or have a negative serum pregnancy test at the time of enrollment
• The patient or legally authorized representative is able to provide informed consent

You cannot join if

• Unable to undergo contrast-enhanced MRI brain
• Leptomeningeal disease confirmed on lumbar puncture, MRI brain, or MRI spine
• Pregnant or lactating women
• Prior brain-directed radiotherapy
• Uncontrolled systemic disease without reasonable systemic therapy options felt likely to result in death as observed on CT or PET/CT imaging, no more than 3 months before study enrollment

This is how the treatment is meant to work. Whether it helps, and how safe it is, is what this trial is testing.

Treatments listed in the registry

• Stereotactic Radiosurgery (Radiation): All participants will undergo MSK standard SRS. A CT simulation will be performed per institutional standards, typically with contrast unless a contraindication exists. A contrast-enhanced MRI with 1mm slices will be fused to the CT simulation scan for the purposes of SRS planning. The SRS GTV will be considered the visible tumor on MRI and CT contrast enhanced studies. An expansion of 1-2mm will be used to create the PTV. Radiation dose may be between 16Gy and 30Gy in 1 to 5 fractions, per the discretion of the treating radiation oncologist. Participants with multiple lesions may receive different doses to each lesion per the discretion of the treating radiation oncologist. Concurrent treatment to other body sites is permitted.
• Cerebrospinal fluid collection (Procedure): All participants will undergo lumbar puncture for CSF collection at study enrollment.. Lumbar punctures will be performed by clinical staff in neurology or neuroradiology, per the discretion of the treating radiation oncologist, as dictated by scheduling limitations and expected clinical difficulty in obtaining a sample (e.g. requiring fluoroscopic guidance), with input from the PI, neurology, and/or neuroradiology as necessary. Participants will be encouraged to undergo repeat lumbar puncture for CSF collection at 3 months (+/- 4 weeks), and at the time of CNS disease progression, though these latter timepoints are not required. CSF cytology will be evaluated.

Na · Single Group · masking: None

As the registry describes them. Requirements to join, such as a tissue sample, are in the eligibility list above even when on-study procedures are optional. Ask the study team which steps apply to you.

• CT scans: Part of the study plan
• MRI: Part of the study plan
• lumbar puncture: Part of the study plan

Main goals

• Overall survival (6 months)

Planned enrollment: 62 (estimated).

• Memorial Sloan Kettering at Basking Ridge, Basking Ridge, New Jersey
• Memorial Sloan Kettering Monmouth, Middletown, New Jersey
• Memorial Sloan Kettering Bergen, Montvale, New Jersey
• Memorial Sloan Kettering Suffolk - Commack, Commack, New York
• Memorial Sloan Kettering Westchester, Harrison, New York
• Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York
• Memorial Sloan Kettering Nassau, Rockville Centre, New York

Site status as of Oct 30, 2026. Check the live record before contacting a site.

• ClinicalTrials.gov NCT05419076

Registry record reviewed as fetched Oct 30, 2026, last updated by the sponsor Jun 9, 2026. Public record; not medical advice.